TG Therapeutics And Neuraxpharm Announced An Agreement For The Ex-US Commercialization Of Briumvi (Ublituximab) For Relapsing Multiple Sclerosis, For Approximately ~$650M, Including Over $150M In Upfront And Near-term Milestones
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics and Neuraxpharm have announced a deal for the ex-US commercialization of Briumvi (Ublituximab) for relapsing multiple sclerosis. The deal is worth approximately $650M, including over $150M in upfront and near-term milestones.
August 01, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics has entered into a significant partnership with Neuraxpharm for the commercialization of Briumvi. This could potentially boost the company's revenues and profitability.
The deal is directly related to TG Therapeutics' product, Briumvi, and is expected to bring in significant revenue for the company. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100